The big question
During breast cancer surgery, doctors usually remove a few lymph nodes from the armpit. This is called a sentinel lymph node biopsy. It is done to check whether cancer has spread, not to cure it. For people with small tumors and a normal armpit ultrasound, is it safe to skip it?
What they did
The SOUND trial enrolled 1,463 women with breast tumors up to 2 cm (under an inch) and a normal armpit ultrasound, in Italy, Switzerland, Spain and Chile. They were randomly assigned to have the lymph node biopsy or no armpit surgery. Researchers analyzed 1,405 of them and followed them for a median of 5.7 years.
What they found
After 5 years, 97.7% of the biopsy group and 98.0% of the no-surgery group were alive and free of cancer spread to distant parts of the body. There were 21 deaths (3.0%) in the biopsy group and 18 (2.6%) in the no-surgery group. In the biopsy group, 13.7% had cancer found in the lymph nodes.
Why it matters
For the right patients, skipping armpit surgery was just as safe. That means one less procedure during treatment.
What it doesn't mean
This applies only to people like those in the trial: small tumors, a normal ultrasound, and mostly hormone-sensitive, HER2-negative cancers. The authors say skipping the biopsy makes sense only when the missing information would not change the rest of the treatment plan. This is a decision for you and your surgeon, not a reason to skip surgery on your own.
Read the original abstract+
Importance: Sentinel lymph node biopsy (SLNB) is the standard of care for axillary node staging of patients with early breast cancer (BC), but its necessity can be questioned since surgery for examination of axillary nodes is not performed with curative intent. Objective: To determine whether the omission of axillary surgery is noninferior to SLNB in patients with small BC and a negative result on preoperative axillary lymph node ultrasonography. Design, Setting, and Participants: The SOUND (Sentinel Node vs Observation After Axillary Ultra-Sound) trial was a prospective noninferiority phase 3 randomized clinical trial conducted in Italy, Switzerland, Spain, and Chile. A total of 1463 women of any age with BC up to 2 cm and a negative preoperative axillary ultrasonography result were enrolled and randomized between February 6, 2012, and June 30, 2017. Of those, 1405 were included in the intention-to-treat analysis. Data were analyzed from October 10, 2022, to January 13, 2023. Intervention: Eligible patients were randomized on a 1:1 ratio to receive SLNB (SLNB group) or no axillary surgery (no axillary surgery group). Main Outcomes and Measures: The primary end point of the study was distant disease-free survival (DDFS) at 5 years, analyzed as intention to treat. Secondary end points were the cumulative incidence of distant recurrences, the cumulative incidence of axillary recurrences, DFS, overall survival (OS), and the adjuvant treatment recommendations. Results: Among 1405 women (median [IQR] age, 60 [52-68] years) included in the intention-to-treat analysis, 708 were randomized to the SLNB group, and 697 were randomized to the no axillary surgery group. Overall, the median (IQR) tumor size was 1.1 (0.8-1.5) cm, and 1234 patients (87.8%) had estrogen receptor-positive ERBB2 (formerly HER2 or HER2/neu), nonoverexpressing BC. In the SLNB group, 97 patients (13.7%) had positive axillary nodes. The median (IQR) follow-up for disease assessment was 5.7 (5.0-6.8) years in the SLNB group and 5.7 (5.0-6.6) years in the no axillary surgery group. Five-year distant DDFS was 97.7% in the SLNB group and 98.0% in the no axillary surgery group (log-rank P = .67; hazard ratio, 0.84; 90% CI, 0.45-1.54; noninferiority P = .02). A total of 12 (1.7%) locoregional relapses, 13 (1.8%) distant metastases, and 21 (3.0%) deaths were observed in the SLNB group, and 11 (1.6%) locoregional relapses, 14 (2.0%) distant metastases, and 18 (2.6%) deaths were observed in the no axillary surgery group. Conclusions and Relevance: In this randomized clinical trial, omission of axillary surgery was noninferior to SLNB in patients with small BC and a negative result on ultrasonography of the axillary lymph nodes. These results suggest that patients with these features can be safely spared any axillary surgery whenever the lack of pathological information does not affect the postoperative treatment plan. Trial Registration: ClinicalTrials.gov Identifier: NCT02167490
Abstract reproduced from Gentilini OD et al., JAMA Oncology (2023), under a CC BY 4.0 license, with punctuation lightly adapted. Plain-English summary by Womanhattan.
This summary was written with AI assistance and checked against the original paper. It is for learning, not medical advice. Talk with your care team before changing anything about your health or treatment.